Search research articles
Contact Us
Filters
Showing results (31-40 of 64) with videos related to
Page
of 7
Sort By:
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
December 17, 2010
Adolescent acromegaly: clinical parameters and treatment outcome
A Bhansali, V Upreti, P Dutta, et al.
Clinical and Translational Science
|
June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development
Johannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Journal of Clinical Pharmacology
|
August 6, 2025
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients
Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose, et al.
Clinical Pharmacology : Advances and Applications
|
May 3, 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Vijay V Upreti, Yan Song, Jessie Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2024
Oncology Combination Drug Development Strategies for Project Optimus
Timothy A Yap, Julie Bullock, Susan Chong, et al.
British Journal of Clinical Pharmacology
|
March 16, 2013
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay V Upreti, Jessie Wang, Yu Chen Barrett, et al.
Proteomics
|
September 10, 2008
Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver
Kwan-Hoon Moon, Vijay V Upreti, Li-Rong Yu, et al.
Clinical Pharmacology and Therapeutics
|
September 16, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager
Di Zhou, Roman Kischel, Sabine Stienen, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2019
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
Christophe Massard, Jean-Charles Soria, Jürgen Krauss, et al.
Cancer Chemotherapy and Pharmacology
|
June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal, Richard Curry, David A Reardon, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 64) with videos related to
Sort By:
Page
of 7
Journal of Pediatric Endocrinology & Metabolism : JPEM
|
December 17, 2010
Adolescent acromegaly: clinical parameters and treatment outcome
A Bhansali, V Upreti, P Dutta, et al.
Clinical and Translational Science
|
June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development
Johannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Journal of Clinical Pharmacology
|
August 6, 2025
Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients
Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose, et al.
Clinical Pharmacology : Advances and Applications
|
May 3, 2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Vijay V Upreti, Yan Song, Jessie Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2024
Oncology Combination Drug Development Strategies for Project Optimus
Timothy A Yap, Julie Bullock, Susan Chong, et al.
British Journal of Clinical Pharmacology
|
March 16, 2013
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
Vijay V Upreti, Jessie Wang, Yu Chen Barrett, et al.
Proteomics
|
September 10, 2008
Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver
Kwan-Hoon Moon, Vijay V Upreti, Li-Rong Yu, et al.
Clinical Pharmacology and Therapeutics
|
September 16, 2024
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager
Di Zhou, Roman Kischel, Sabine Stienen, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2019
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
Christophe Massard, Jean-Charles Soria, Jürgen Krauss, et al.
Cancer Chemotherapy and Pharmacology
|
June 3, 2019
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Mark Rosenthal, Richard Curry, David A Reardon, et al.
Page
of 7